The decision by the federal government to institute uniform national coverage for the treatment of actinic keratoses elicited a resoundingly favorable response from the dermatological community.
Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment
New Dermatology Social Comparison Scale Demonstrates Acceptable Psychometrics for Clinical and Research Applications
ReV Up Your Vitiligo Treatment Strategies
A Novel Approach to Distinguishing Scabies From Atopic Dermatitis
Secukinumab Demonstrates Promise for Patients With Severe Hidradenitis Suppurativa Who Found Adalimumab Intolerable